Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q8IYI6
UPID:
EXOC8_HUMAN
Alternative names:
Exocyst complex 84 kDa subunit
Alternative UPACC:
Q8IYI6; B3KU33; Q5TE82
Background:
Exocyst complex component 8, also known as the 84 kDa subunit, plays a crucial role in cellular processes by being a part of the exocyst complex. This complex is essential for the docking of exocytic vesicles with fusion sites on the plasma membrane, a process vital for the delivery of cellular cargo and membrane expansion.
Therapeutic significance:
The protein is linked to a neurodevelopmental disorder characterized by microcephaly, seizures, and brain atrophy. Understanding the role of Exocyst complex component 8 could open doors to potential therapeutic strategies for this severe condition.